司美格鲁肽治疗成人非2型糖尿病超重和肥胖患者效果的Meta分析  

Efficacy of semaglutide in weight loss of overweight or obese people with non-type 2 diabetes:a Meta analysis

作　　者：双丹丹 张惠莉[2] SHUANG Dandan;ZHANG Huili(Graduate School of Qinghai University,Xining 810016,China;不详)

机构地区：[1]青海大学研究生院,西宁810016 [2]青海大学附属医院内分泌科,西宁810012

出　　处：《实用医学杂志》2023年第3期343-349,共7页The Journal of Practical Medicine

基　　金：青海省科技厅基础研究基金项目(编号:2019-ZJ-7079)。

摘　　要：目的 评价司美格鲁肽治疗成人非2型糖尿病超重和肥胖患者的效果。方法 检索Cochrane Library、Embase、PubMed、中国知网、万方数据知识服务平台及中国生物医学文献服务系统等六大数据库中建库至2022年4月的有关司美格鲁肽与安慰剂或其他药物对照治疗成人非2型糖尿病超重和肥胖患者的随机对照试验(randomised controlled trials,RCTs)。运用RevMan 5.4.1对符合纳入与排除标准的RCTs进行Meta分析。结果 最终纳入6篇RCTs,成人非2型糖尿病超重和肥胖患者共计4 137例。Meta分析结果表明,司美格鲁肽组体质量下降百分比高于安慰剂组和利拉鲁肽组[MD=-12.87,95%CI(-14.28~-11.46),P <0.05;MD=-7.18,95%CI(-10.95~-3.41),P <0.05];司美格鲁肽组体质量下降值大于安慰剂组和利拉鲁肽组[MD=-12.58,95%CI(-14.07~-11.09),P <0.05;MD=-7.23,95%CI(-9.99~-4.48),P <0.05];司美格鲁肽组体质量下降≥5%、≥10%以及≥15%的患者比例均高于安慰剂组和利拉鲁肽组[OR=8.90,95%CI(6.08~13.04),P <0.05;OR=3.59,95%CI(2.26~5.69),P <0.05]、[OR=12.45,95%CI(8.91~17.39),P <0.05;OR=5.02,95%CI(2.56~9.84),P <0.05]、[OR=14.36,95%CI(9.39~21.96),P <0.05;RR=3.71,95%CI(2.57~5.34),P <0.05]。结论 司美格鲁肽治疗成人非2型糖尿病超重和肥胖患者有显著的减重效果,且优于利拉鲁肽。Objective To evaluate the efficacy of semaglutide in the treatment of overweight and obese adults with non-type 2 diabetes.Methods The randomized controlled trials(RCTs)of semaglutide versus placebo or other drugs in the treatment of overweight and obese adults with non-type 2 diabetes were retrieved from six databases including the Cochrane Library,Embase,PubMed,CNKI,Wanfang data knowledge service platform and China biomedical literature service system as of April 2022.Revman 5.4.1 was applied to meta-analysis of RCTs that met the inclusion and exclusion criteria.Results Six RCTs were finally included,and 4137 adult patients with non-type 2 diabetes were overweight and obese.The results of meta-analysis showed that the percentage of decrease in body mass in semaglutide group was higher than that in placebo group and liraglutide group[MD=-12.87,95%CI(-14.28,-11.46),P<0.05;MD=-7.18,95%CI(-10.95,-3.41),P<0.05];the decrease of body mass in semaglutide group was greater than that in placebo group and liraglutide group[MD=-12.58,95%CI(-14.07,-11.09),P<0.05;MD=-7.23,95%CI(-9.99,-4.48),P<0.05];the proportion of patients with≥5%,≥10%and≥15%decrease in body mass in semaglutide group was higher than that in placebo group and liraglutide group[OR=8.90,95%CI(6.08,13.04),P<0.05;OR=3.59,95%CI(2.26,5.69),P<0.05],[OR=12.45,95%CI(8.91,17.39),P<0.05;OR=5.02,95%CI(2.56,9.84),P<0.05],[OR=14.36,95%CI(9.39,21.96),P<0.05;RR=3.71,95%CI(2.57,5.34),P<0.05].Conclusion Semaglutide has significant weight loss effect in the treatment of overweight and obese adults with non-type 2 diabetes,and is superior to liraglutide.

关 键 词：司美格鲁肽 超重 肥胖 非2型糖尿病 META分析 

分 类 号：R977.15[医药卫生—药品]